Admelog Solostar is a drug owned by Sanofi-aventis Us Llc. It is protected by 19 US drug patents filed in 2018. Out of these, 3 drug patents are active and 16 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 08, 2033. Details of Admelog Solostar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9717852 | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | Active |
| US7918833 | Pen-type injector |
Sep, 2027
(2 years from now) | Active |
| US8679069 | Pen-type injector |
Apr, 2025
(4 months from now) | Active |
| US8512297 | Pen-type injector |
Sep, 2024
(2 months ago) |
Expired
|
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(2 months ago) |
Expired
|
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(2 months ago) |
Expired
|
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(2 months ago) |
Expired
|
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(2 months ago) |
Expired
|
| US8992486 | Pen-type injector |
Jun, 2024
(5 months ago) |
Expired
|
| US9011391 | Pen-type injector |
Mar, 2024
(7 months ago) |
Expired
|
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(8 months ago) |
Expired
|
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(8 months ago) |
Expired
|
| US9526844 | Pen-type injector |
Mar, 2024
(8 months ago) |
Expired
|
| US9408979 | Pen-type injector |
Mar, 2024
(8 months ago) |
Expired
|
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(8 months ago) |
Expired
|
| US9775954 | Pen-type injector |
Mar, 2024
(8 months ago) |
Expired
|
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(8 months ago) |
Expired
|
| US8603044 | Pen-type injector |
Mar, 2024
(8 months ago) |
Expired
|
| US9233211 | Relating to a pen-type injector |
Mar, 2024
(8 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Admelog Solostar's patents.
Latest Legal Activities on Admelog Solostar's Patents
Given below is the list of recent legal activities going on the following patents of Admelog Solostar.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9233211 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011391 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7918833 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US8992486 (Litigated) |
| Review Certificate Mailed | 30 Aug, 2022 | US9526844 |
| Review Certificate Mailed | 26 Aug, 2022 | US8603044 |
| Review Certificate Mailed | 18 Aug, 2022 | US8992486 (Litigated) |
| Review Certificate Mailed | 18 Aug, 2022 | US9604008 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Admelog Solostar and ongoing litigations to help you estimate the early arrival of Admelog Solostar generic.
Admelog Solostar's Litigations
Admelog Solostar been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 10, 2018, against patent number US8992486. The petitioner Mylan Pharmaceuticals Inc et al., challenged the validity of this patent, with Sanofi-Aventis Deutschland GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Admelog Solostar's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8679069 | May, 2019 |
FWD Entered
(11 Aug, 2020) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | September, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | October, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9604008 | September, 2018 |
FWD Entered
(29 May, 2020) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8679069 | September, 2018 |
FWD Entered
(02 Apr, 2020) | Sanofi-Aventis Deutshland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(20 Aug, 2019) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(19 Aug, 2019) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | May, 2019 |
Terminated-Other
(15 Aug, 2019) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8992486 | May, 2019 |
Terminated-Other
(15 Aug, 2019) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9604008 | May, 2019 |
Terminated-Other
(15 Aug, 2019) | Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | September, 2018 |
Terminated-Denied
(03 Apr, 2019) | Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
Terminated
(19 Dec, 2018) | Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
FDA has granted some exclusivities to Admelog Solostar. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Admelog Solostar, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Admelog Solostar.
Exclusivity Information
Admelog Solostar holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Admelog Solostar's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
US patents provide insights into the exclusivity only within the United States, but Admelog Solostar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Admelog Solostar's family patents as well as insights into ongoing legal events on those patents.
Admelog Solostar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Admelog Solostar's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 08, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Admelog Solostar Generics:
There are no approved generic versions for Admelog Solostar as of now.
Alternative Brands for Admelog Solostar
Admelog Solostar which is used for improving glycemic control in diabetes mellitus patients., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Lispro). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Sanofi Aventis Us |
| |||||
| Sanofi-aventis Us |
| |||||
| Sanofi Us Services |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Insulin Lispro. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||||||
|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co |
| |||||||
| Lilly |
|
About Admelog Solostar
Admelog Solostar is a drug owned by Sanofi-Aventis Us Llc. It is used for improving glycemic control in diabetes mellitus patients. Admelog Solostar uses Insulin Lispro as an active ingredient. Admelog Solostar was launched by Sanofi-Aventis Us in 2017.
Approval Date:
Admelog Solostar was approved by FDA for market use on 11 December, 2017.
Active Ingredient:
Admelog Solostar uses Insulin Lispro as the active ingredient. Check out other Drugs and Companies using Insulin Lispro ingredient
Treatment:
Admelog Solostar is used for improving glycemic control in diabetes mellitus patients.
Dosage:
Admelog Solostar is available in solution form for intravenous, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300 UNITS/3ML (100 UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS, SUBCUTANEOUS |